Cell Division Cycle 7 Related Protein Kinase (CDC7-Related Kinase or HsCdc7 or EC 2.7.11.1) - Pipeline Review, H1 2016

  • ID: 3802729
  • Report
  • 32 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • Amgen Inc.
  • ProNAi Therapeutics, Inc.
  • SBI Biotech Co., Ltd.
  • MORE
Cell Division Cycle 7 Related Protein Kinase (CDC7-Related Kinase or HsCdc7 or EC 2.7.11.1) - Pipeline Review, H1 2016

Summary

‘Cell Division Cycle 7 Related Protein Kinase (CDC7-Related Kinase or HsCdc7 or EC 2.7.11.1) - Pipeline Review, H1 2016’, provides in depth analysis on Cell Division Cycle 7 Related Protein Kinase (CDC7-Related Kinase or HsCdc7 or EC 2.7.11.1) targeted pipeline therapeutics.

The report provides comprehensive information on the Cell Division Cycle 7 Related Protein Kinase (CDC7-Related Kinase or HsCdc7 or EC 2.7.11.1), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Cell Division Cycle 7 Related Protein Kinase (CDC7-Related Kinase or HsCdc7 or EC 2.7.11.1) targeted therapeutics development and features dormant and discontinued projects.

The author's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from their proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for Cell Division Cycle 7 Related Protein Kinase (CDC7-Related Kinase or HsCdc7 or EC 2.7.11.1)
- The report reviews Cell Division Cycle 7 Related Protein Kinase (CDC7-Related Kinase or HsCdc7 or EC 2.7.11.1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Cell Division Cycle 7 Related Protein Kinase (CDC7-Related Kinase or HsCdc7 or EC 2.7.11.1) targeted therapeutics and enlists all their major and minor projects
- The report assesses Cell Division Cycle 7 Related Protein Kinase (CDC7-Related Kinase or HsCdc7 or EC 2.7.11.1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Cell Division Cycle 7 Related Protein Kinase (CDC7-Related Kinase or HsCdc7 or EC 2.7.11.1) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Cell Division Cycle 7 Related Protein Kinase (CDC7-Related Kinase or HsCdc7 or EC 2.7.11.1)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Cell Division Cycle 7 Related Protein Kinase (CDC7-Related Kinase or HsCdc7 or EC 2.7.11.1) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Amgen Inc.
  • ProNAi Therapeutics, Inc.
  • SBI Biotech Co., Ltd.
  • MORE
List of Tables

List of Figures

Introduction

Report Coverage

Cell Division Cycle 7 Related Protein Kinase (CDC7-Related Kinase or HsCdc7 or EC 2.7.11.1) Overview

Therapeutics Development

Cell Division Cycle 7 Related Protein Kinase (CDC7-Related Kinase or HsCdc7 or EC 2.7.11.1) - Products under Development by Stage of Development

Cell Division Cycle 7 Related Protein Kinase (CDC7-Related Kinase or HsCdc7 or EC 2.7.11.1) - Products under Development by Therapy Area

Cell Division Cycle 7 Related Protein Kinase (CDC7-Related Kinase or HsCdc7 or EC 2.7.11.1) - Products under Development by Indication

Cell Division Cycle 7 Related Protein Kinase (CDC7-Related Kinase or HsCdc7 or EC 2.7.11.1) - Pipeline Products Glance

Early Stage Products

Cell Division Cycle 7 Related Protein Kinase (CDC7-Related Kinase or HsCdc7 or EC 2.7.11.1) - Products under Development by Companies

Cell Division Cycle 7 Related Protein Kinase (CDC7-Related Kinase or HsCdc7 or EC 2.7.11.1) - Products under Development by Universities/Institutes

Cell Division Cycle 7 Related Protein Kinase (CDC7-Related Kinase or HsCdc7 or EC 2.7.11.1) - Therapeutics Assessment

Assessment by Monotherapy/Combination Products

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Cell Division Cycle 7 Related Protein Kinase (CDC7-Related Kinase or HsCdc7 or EC 2.7.11.1) - Companies Involved in Therapeutics Development

Amgen Inc.

Millennium Pharmaceuticals, Inc.

ProNAi Therapeutics, Inc.

SBI Biotech Co., Ltd.

Cell Division Cycle 7 Related Protein Kinase (CDC7-Related Kinase or HsCdc7 or EC 2.7.11.1) - Drug Profiles

MSK-777 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PNT-141 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Inhibit Cdc7/ASK for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit CDC-7 for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit CDC7 for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TAK-931 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Cell Division Cycle 7 Related Protein Kinase (CDC7-Related Kinase or HsCdc7 or EC 2.7.11.1) - Dormant Projects

Cell Division Cycle 7 Related Protein Kinase (CDC7-Related Kinase or HsCdc7 or EC 2.7.11.1) - Discontinued Products

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer 32List of Tables

Number of Products under Development for, H1 2016

Number of Products under Development by Therapy Area, H1 2016

Number of Products under Development by Indication, H1 2016

Comparative Analysis by Early Stage Products, H1 2016

Number of Products under Development by Companies, H1 2016

Products under Development by Companies, H1 2016

Number of Products under Investigation by Universities/Institutes, H1 2016

Products under Investigation by Universities/Institutes, H1 2016

Assessment by Monotherapy/Combination Products, H1 2016

Number of Products by Stage and Mechanism of Action, H1 2016

Number of Products by Stage and Route of Administration, H1 2016

Number of Products by Stage and Molecule Type, H1 2016

Pipeline by Amgen Inc., H1 2016

Pipeline by Millennium Pharmaceuticals, Inc., H1 2016

Pipeline by ProNAi Therapeutics, Inc., H1 2016

Pipeline by SBI Biotech Co., Ltd., H1 2016

Dormant Projects, H1 2016

Discontinued Products, H1 2016 30List of Figures

Number of Products under Development for, H1 2016

Number of Products under Development by Indication, H1 2016

Comparative Analysis by Early Stage Products, H1 2016

Assessment by Monotherapy/Combination Products, H1 2016

Number of Products by Stage and Mechanism of Actions, H1 2016

Number of Products by Stage and Routes of Administration, H1 2016

Number of Products by Stage and Molecule Type, H1 2016
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5

FEATURED COMPANIES

  • Amgen Inc.
  • ProNAi Therapeutics, Inc.
  • SBI Biotech Co., Ltd.
  • MORE
Cell Division Cycle 7 Related Protein Kinase (CDC7-Related Kinase or HsCdc7 or EC 2.7.11.1) Cell division cycle 7-related protein kinase is an enzyme encoded by the CDC7 gene. It phosphorylate substrates that regulate the G1/S phase transition and DNA replication. Overexpression of CDC7 is associated with neoplastic transformation for some tumors.

Cell Division Cycle 7 Related Protein Kinase (CDC7-Related Kinase or HsCdc7 or EC 2.7.11.1) pipeline Target constitutes close to 6 molecules. Out of which approximately 4 molecules are developed by Companies and remaining by the Universities/Institutes. The molecules developed by Companies in Phase I, Preclinical and Discovery stages are 1, 2 and 1 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 2 molecules, respectively.

The author's latest report Cell Division Cycle 7 Related Protein Kinase - Pipeline Review, H1 2016, outlays comprehensive information on the Cell Division Cycle 7 Related Protein Kinase (CDC7-Related Kinase or HsCdc7 or EC 2.7.11.1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Cell Division Cycle 7 Related Protein Kinase (CDC7-Related Kinase or HsCdc7 or EC 2.7.11.1) targeted therapeutics development, features dormant and discontinued projects and latest news and press releases.

The report is built using data and information sourced from their proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Note: Product cover images may vary from those shown
5 of 5
Amgen Inc.
Millennium Pharmaceuticals, Inc.
ProNAi Therapeutics, Inc.
SBI Biotech Co., Ltd.
Note: Product cover images may vary from those shown
6 of 5
Note: Product cover images may vary from those shown
Adroll
adroll